|
Product Report
|
 Disease Modification in Rheumatoid Arthritis - Competition for the anti-TNF failure
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF's is reaching a maximum and competition moves to anti-TNF failure patients.
|
|
Read more...
|
|
|
Market Report
|
Fibromyalgia - Potentially lucrative market soon to become reality
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.
|
|
Read more...
|
|
|
Market Report
|
An Introduction to the Canadian Generics Market - Key trends and leading companies shaping the market
The Canadian pharmaceutical market is the 8th largest globally and as such represents an important market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players.
|
|
Read more...
|
|
|
Market Report
|
Female Sexual Dysfunction - Results from Datamonitor's 2005 physician survey
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.
|
|
Read more...
|
|
|
Market Report
|
Supportive Care in Oncology-Significant growth opportunities in new supportive care indications
Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.
|
|
Read more...
|
|
|
Market Report
|
Hepatocellular Carcinoma - Opportune indication for novel therapies
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.
|
|
Read more...
|
|
|
Market Report
|
Irritable Bowel Syndrome -Potentially profitable market is open for the taking
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.
|
|
Read more...
|
|
|
Market Report
|
Monoclonal Antibodies Report Part I
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
|
|
Read more...
|
|
|
Market Report
|
Depression - Atypical lifecycle management strategy rejuvenates depression market
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.
|
|
Read more...
|
|
|
Market Report
|
Insomnia-Strong brand identity critical to differentiation in an increasingly crowded market
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambien's leadership status is finally under threat and the market is undergoing some dramatic changes.
|
|
Read more...
|
|
|
Market Report
|
Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
|
|
Read more...
|
|
|
Market Report
|
Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.
|
|
Read more...
|
|
|
Market Report
|
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders.
|
|
Read more...
|
|
|
Market Report
|
Asthma & COPD - Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
|
|
Read more...
|
|
|
Market Report
|
HIV - Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.
|
|
Read more...
|
|
|
Market Report
|
Upper GI Disorders - Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
|
|
Read more...
|
|
|
Market Report
|
The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
|
|
Read more...
|
|
|
Market Report
|
New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
Farmavita.Net Journal 
